| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Kansuinine B targets the IL-6/Stat3 signaling pathway. By inhibiting IL-6-induced Stat3 activation, the compound modulates inflammatory and immune responses. Stat3 is a transcription factor that plays a critical role in cell proliferation, survival, and inflammation. The compound's inhibition of Stat3 activation underlies its anti-inflammatory and immunoregulatory activities.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, Kansuinine B inhibits IL-6-induced Stat3 activation. The compound's inhibition of Stat3 can be assessed using cell-free assays with purified Stat3 protein and its upstream kinases. The compound shows cytotoxic activity in cell-free systems. It also exhibits antiviral activity.
|
| ln Vivo |
In cell-based assays, Kansuinine B inhibits IL-6-induced Stat3 activation, leading to reduced inflammatory responses. The compound shows cytotoxic activity against cancer cells and possesses immunoregulatory activity. It has been studied for antiviral host response pathways and could be used in the study for COVID-19.
|
| Enzyme Assay |
The cell-free assay for Stat3 activation involves measuring the phosphorylation of Stat3 protein. The compound is incubated with purified Stat3 and its upstream kinases in the presence of IL-6, and the phosphorylation of Stat3 is measured using Western blotting or ELISA. The compound's inhibition of Stat3 activation is determined from dose-response curves. Cytotoxicity can be assessed using standard cell-free assays.
|
| Cell Assay |
Cell-based assays for Kansuinine B involve culturing relevant cell lines and treating them with the compound at concentrations ranging from 0.1 to 100 μM. IL-6-induced Stat3 activation is assessed by measuring Stat3 phosphorylation by Western blotting. Cell viability is assessed using MTT or CCK-8 assays. Antiviral activity is assessed by measuring viral replication in infected cells. The compound's immunoregulatory effects are evaluated by measuring cytokine production.
|
| Animal Protocol |
There is no established animal experimental protocol for Kansuinine B specifically. As a natural compound with anti-inflammatory, immunoregulatory, and antiviral activities, it could potentially be evaluated in animal models of inflammation, viral infection, or cancer. Typical studies involve administration of the compound to mice via oral or intraperitoneal routes. Inflammatory markers, viral load, and tumor growth would be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Kansuinine B have not been extensively reported. As a complex natural product with a molecular weight of 722.73 g/mol, the compound would be expected to have limited oral bioavailability and may require parenteral administration. The compound is typically stored at low temperatures for research use. Further pharmacokinetic studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
Kansuinine B is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this natural product. As a compound with cytotoxic and immunomodulatory activities, it may have effects on normal cells as well as cancer cells. Standard toxicity studies would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
Kansuinine B is a benzoic acid ester. It has been reported that Kansuinine B exists in the genus Euphorbia kansui, and relevant data are available for reference.
Kansuinine B is a research-grade natural product from Euphorbia kansui L. It is not an approved pharmaceutical and has no clinical trial history. The compound inhibits IL-6-induced Stat3 activation, possesses antiviral activity, and could be used in the study for COVID-19. It also shows cytotoxic and analgesic activities. This product is intended for research use only. |
| Molecular Formula |
C38H42O14
|
|---|---|
| Molecular Weight |
722.73
|
| Exact Mass |
722.257
|
| CAS # |
57685-46-8
|
| PubChem CID |
442050
|
| Appearance |
White to off-white solid powder
|
| Source |
Originated from plants: Euphorbiaceae Euphorbia kansui T. N. Liou ex S. B. Ho
|
| LogP |
1.911
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
52
|
| Complexity |
1460
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C[C@H]1[C@H]2[C@@H](O2)C(C(=O)[C@@H]([C@H](C(=C)[C@@H]([C@H]3[C@H]([C@]([C@@H]([C@@]3(C1=O)OC(=O)C)O)(C)O)OC(=O)C)OC(=O)C4=CC=CC=C4)OC(=O)C5=CC=CC=C5)O)(C)C
|
| InChi Key |
JFOILMZFESGPDU-GXRLDEOZSA-N
|
| InChi Code |
InChI=1S/C38H42O14/c1-18-26(50-33(44)22-14-10-8-11-15-22)24-31(48-20(3)39)37(7,47)35(46)38(24,52-21(4)40)29(42)19(2)28-32(49-28)36(5,6)30(43)25(41)27(18)51-34(45)23-16-12-9-13-17-23/h8-17,19,24-28,31-32,35,41,46-47H,1H2,2-7H3/t19-,24-,25+,26-,27-,28-,31+,32+,35-,37-,38+/m0/s1
|
| Chemical Name |
[(1S,3S,4S,6S,9R,10S,12R,13S,14R,15R,16S)-1,14-diacetyloxy-10-benzoyloxy-9,15,16-trihydroxy-3,7,7,15-tetramethyl-11-methylidene-2,8-dioxo-5-oxatricyclo[11.3.0.04,6]hexadecan-12-yl] benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~25 mg/mL (~34.6 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (1.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (1.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3836 mL | 6.9182 mL | 13.8364 mL | |
| 5 mM | 0.2767 mL | 1.3836 mL | 2.7673 mL | |
| 10 mM | 0.1384 mL | 0.6918 mL | 1.3836 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
